Did you know…
Human skin loses more than 50% of its NAD+ across adult life. But NAD+ decline is not uniform across tissues. Skeletal muscle drops roughly 10% per decade. Brain NAD+ shows a more modest 10 to 25% decline from young adulthood to old age, with some recent measurements finding no statistically significant difference between young and older subjects. The dramatic “our NAD+ plummets to half by middle age” figure applies to skin, not to every tissue of the body.
The claim, in the reference of NAD+ biology
The most comprehensive tissue-by-tissue picture comes from a growing consensus across multiple laboratories, summarized recently in the Annual Review of Nutrition and in reviews such as those from David Sinclair’s group at Harvard and Eric Verdin’s at the Buck Institute. The picture is nuanced:
- Skin: accelerated NAD+ loss beginning in the fifth decade, cumulative loss above 50% across adult life.
- Skeletal muscle: approximately 10% decrease per decade in older adults.
- Brain: 10 to 25% drop from young adulthood to old age, with substantial inter-individual variance and at least one recent study finding no significant difference between subjects averaging 21 years and 69 years.
- Liver: slower decline with greater inter-individual variance.
The generalization that NAD+ “plummets to half of youth levels by middle age” oversimplifies. The specific tissue matters. Skin is where the dramatic decline is real. Brain and muscle are where the picture is more mixed.
Why this still matters clinically
NAD+ is the central redox cofactor of cellular metabolism and the substrate for sirtuins, PARPs, and CD38, three enzyme families involved in DNA repair, gene silencing, and inflammation. Even a modest tissue-level decline, when combined with mitochondrial dysfunction and increased CD38 activity in aging, produces functional consequences. The interventions (nicotinamide riboside, nicotinamide mononucleotide) are being trialed. Blood NAD+ measurement, one of the few markers available to the general public, correlates only weakly with tissue NAD+ and should not be over-interpreted.
What clinical care does with any of this
Nothing. NAD+ is not in any standard laboratory panel. Its tissue-specific decline is not a variable primary care is trained to think about. The interventional literature is growing, and the framework for a physiological right to adequate NAD+ status remains, for now, a research question rather than a clinical entitlement.
This entry connects to the emerging framework on conditionally essential and age-declining metabolites, and to the broader question of what a right to physiological maintenance would look like.